Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity-Reference-Cited by-同舟云学术

Discovery of Insulin/GLP-1/Glucagon Triagonists for the Treatment of Diabetes and Obesity

Published:2022-07-21 Issue:8 Volume:13 Page:1255-1261
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Huang Chunhui¹^ORCID,Palani Anandan¹^ORCID,Yang Zhiqiang²,Deng Qiaolin²^ORCID,Reddy Vijay²,Nargund Ravi P.²,Lin Songnian²,Altezza Simona³,Bianchi Elisabetta³^ORCID,Orvieto Federica³,Carrington Paul²

Affiliation:

1. Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

2. Merck & Co., Inc., 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States

3. Peptide Chemistry Unit, Peptides and Small Molecules R&D, IRBM S.p.A., Via Pontina km 30600, 00071 Pomezia (RM), Italy

Funder

Merck Sharp and Dohme

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00218

Reference30 articles.

1. Anti-obesity drug discovery: advances and challenges

2. Mechanisms linking obesity to insulin resistance and type 2 diabetes

3. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017

4. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

5. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultra-stable insulin-glucagon fusion protein exploits an endogenous hepatic switch to mitigate hypoglycemic risk;2024-05-21